Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniele Ouellet

Showing results (11-20 of 61) with videos related to

Pageof 7
Sort By:
Journal of Clinical Pharmacology|December 15, 2010
Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosingSiobhan Hayes, Daniele Ouellet, Jianping Zhang, et al.
Journal of Clinical Pharmacology|January 7, 2006
A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairmentCandace Bramson, Daniele Ouellet, Doina Roman, et al.
Cancer Chemotherapy and Pharmacology|June 9, 2018
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposureJan de Jong, Nahor Haddish-Berhane, Peter Hellemans, et al.
Clinical and Translational Science|October 23, 2025
Application of Machine Learning for Predicting Progression-Free and Overall Survival in Patients With Renal Cell CarcinomaCaroline W Grant, Jerry Li, Swan Lin, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2013
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopeniaSiobhan Hayes, Paul N Mudd, Daniele Ouellet, et al.
Journal of Pharmaceutical Sciences|March 10, 2010
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measureMohamed A Kamal, David E Smith, Jack Cook, et al.
British Journal of Clinical Pharmacology|August 22, 2009
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunitBrian Corrigan, Douglas E Feltner, Daniele Ouellet, et al.
Journal of Clinical Pharmacology|January 11, 2014
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolitesDaniele Ouellet, Ekaterina Gibiansky, Cathrine Leonowens, et al.
Cancer Chemotherapy and Pharmacology|October 30, 2017
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT studyJan de Jong, Peter Hellemans, James Juhui Jiao, et al.
Journal of Clinical Pharmacology|November 20, 2019
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 StudiesAnne-Gaelle Dosne, Elodie Valade, Kim Stuyckens, et al.
Pageof 7

Showing results (11-20 of 61) with videos related to

Sort By:
Pageof 7
Journal of Clinical Pharmacology|December 15, 2010
Population PK/PD modeling of eltrombopag in healthy volunteers and patients with immune thrombocytopenic purpura and optimization of response-guided dosingSiobhan Hayes, Daniele Ouellet, Jianping Zhang, et al.
Journal of Clinical Pharmacology|January 7, 2006
A single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairmentCandace Bramson, Daniele Ouellet, Doina Roman, et al.
Cancer Chemotherapy and Pharmacology|June 9, 2018
The pH-altering agent omeprazole affects rate but not the extent of ibrutinib exposureJan de Jong, Nahor Haddish-Berhane, Peter Hellemans, et al.
Clinical and Translational Science|October 23, 2025
Application of Machine Learning for Predicting Progression-Free and Overall Survival in Patients With Renal Cell CarcinomaCaroline W Grant, Jerry Li, Swan Lin, et al.
Cancer Chemotherapy and Pharmacology|April 9, 2013
Population PK/PD modeling of eltrombopag in subjects with advanced solid tumors with chemotherapy-induced thrombocytopeniaSiobhan Hayes, Paul N Mudd, Daniele Ouellet, et al.
Journal of Pharmaceutical Sciences|March 10, 2010
Pharmacodynamic differentiation of lorazepam sleepiness and dizziness using an ordered categorical measureMohamed A Kamal, David E Smith, Jack Cook, et al.
British Journal of Clinical Pharmacology|August 22, 2009
Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunitBrian Corrigan, Douglas E Feltner, Daniele Ouellet, et al.
Journal of Clinical Pharmacology|January 11, 2014
Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolitesDaniele Ouellet, Ekaterina Gibiansky, Cathrine Leonowens, et al.
Cancer Chemotherapy and Pharmacology|October 30, 2017
Ibrutinib does not prolong the corrected QT interval in healthy subjects: results from a thorough QT studyJan de Jong, Peter Hellemans, James Juhui Jiao, et al.
Journal of Clinical Pharmacology|November 20, 2019
Population Pharmacokinetics of Total and Free Erdafitinib in Adult Healthy Volunteers and Cancer Patients: Analysis of Phase 1 and Phase 2 StudiesAnne-Gaelle Dosne, Elodie Valade, Kim Stuyckens, et al.
Pageof 7